Note: this section is necessarily speculative for a healthy normotensive user. The subjective signature below is synthesized from clinical reports, athletic-patient feedback, and head-to-head comparator data.

First few doses:

• Mild fatigue possible in first 1-3 days as HR drops to new baseline; usually resolves.
• Resting HR drops 5-10 bpm.
• BP drops 6-12 mmHg systolic (more in hypertensives, less in normotensives).
• Less peripheral cooling than older beta-blockers. Hands and feet do NOT typically feel cold the way they do on metoprolol or propranolol — this is the NO-arm signature.
• No notable cognitive change. Minimal CNS penetration relative to propranolol.
• Sleep usually unaffected; some users report mildly improved sleep latency from lower sympathetic tone.

Steady state (week 2+):

• Resting HR settles 8-15 bpm below baseline at standard dose.
• BP control stable.
• Exercise tolerance: max HR is capped (β1 blockade — physically cannot reach the same peak HR), but time-to-exhaustion at submax efforts is much closer to baseline than on older beta-blockers. The reason: cardiac output is preserved better via reduced afterload (peripheral vasodilation), and skeletal-muscle β2 signaling is preserved.
• Sexual function: largely preserved. Where metoprolol/atenolol cause measurable ED in 5-15% of users at chronic dose, nebivolol produces ED in ~2-5% — close to placebo rates in some studies.
• No characteristic "beta-blocker fatigue." This is the dominant subjective contrast vs. older agents.

Athletic context (extrapolated for this user's profile if he ever needed it):

• Cardio capacity penalty: real but smaller than older beta-blockers. Max HR cap of ~15-25 bpm at therapeutic dose. For high-intensity intervals and rounds, this is a real limit. For zone 2 work and technical drilling, much closer to baseline than on metoprolol/atenolol.
• Strength/power: minimally affected. β1-selectivity preserves the β2-mediated lipolysis and fiber recruitment that older non-selective beta-blockers blunt.
• Recovery: probably neutral or slightly improved vs. older beta-blockers, given preserved peripheral perfusion and reduced cardiovascular strain.
• Subjective sense of "gas tank": much closer to baseline than on propranolol or metoprolol. Patients on metoprolol routinely report "feeling like the engine is half-size"; patients on nebivolol describe "lower idle, same usable range."

What it does NOT do (relative to other beta-blockers):

• Does NOT reliably suppress somatic anxiety / tremor / voice shake the way propranolol does. Propranolol's β2-blockade is the active mechanism for tremor suppression; nebivolol largely spares β2 and so is not a stage-fright tool. If somatic performance anxiety is the indication, propranolol is right and nebivolol is wrong.
• Does NOT cause cold extremities or peripheral discomfort the way older beta-blockers reliably do.
• Does NOT cause measurable ED at the rates older beta-blockers do.
• Does NOT meaningfully impair exercise tolerance the way older beta-blockers do at equipotent doses.
• Does NOT mask hypoglycemia adrenergic warnings as severely as non-selective propranolol (high β1-selectivity preserves glycogenolysis and the tachycardia warning sign).
• Does NOT cross BBB significantly; no central-anxiolytic effect, no PTSD-reconsolidation utility (those are propranolol-only).

• Tolerance buildup at chronic dosing: minimal. Beta-blocker pharmacology is competitive antagonism; receptor up-regulation occurs over weeks (which is why abrupt cessation causes rebound) but the therapeutic effect is preserved. No dose-escalation is typical.
• Cycling: not applicable. Nebivolol is a chronic-use medication, not a PRN tool. Use is continuous if indicated.
• Discontinuation requires taper. Never abrupt.
• Frequency ceiling: not applicable — daily dosing is the protocol.

Synergistic with (in HTN context)

• Telmisartan or other ARB. ACE/ARB + beta-blocker is a guideline-recommended combination for HTN with comorbidities (CAD, post-MI, HF). For an athletic HTN user, telmisartan + nebivolol is the cleanest combo profile.
• Calcium channel blockers (amlodipine, dihydropyridine class). Beta-blocker + DHP-CCB is a standard 2nd-line HTN combination; works synergistically (HR control + peripheral vasodilation).
• Hydrochlorothiazide / chlorthalidone (low-dose). Standard 2nd/3rd-line HTN add-on.
• Statin (atorvastatin/rosuvastatin) for primary prevention. Standard CV-risk-reduction stack.

Avoid stacking with

• Verapamil or diltiazem (non-DHP CCBs). Additive bradycardia and AV-conduction depression — high risk of symptomatic bradyarrhythmia or block. Standard contraindication for any beta-blocker.
• Other beta-blockers. Redundant + risk of excessive blockade.
• Clonidine (rebound HTN if either withdrawn).
• CYP2D6 strong inhibitors (paroxetine, fluoxetine, bupropion, quinidine, terbinafine). Raise nebivolol exposure substantially (effectively converting EM to PM phenotype). If unavoidable, halve nebivolol dose.

Neutral / safe co-administration (relevant to this archetype's stack)

• Modafinil / armodafinil: No significant interaction — modafinil is a CYP3A4 substrate and weak inducer; nebivolol is CYP2D6. The HR-elevation effect of modafinil is partially offset by nebivolol (which is sometimes the practical reason to combine). Acceptable.
• Telmisartan: Synergistic for HTN; safe combo.
• L-theanine, magnesium glycinate, taurine: All safe. Mild additive on resting HR/BP via parasympathetic tone, but clinically negligible.
• Creatine, beta-alanine, citrulline, omega-3: All safe. Citrulline + nebivolol is theoretically synergistic on NO bioavailability but no clinical signal of significance.
• Most peptides (BPC-157, TB-500, ipamorelin, CJC-1295): no known interactions.
• Most racetams + cholines: safe.
• AAS / TRT: No direct PK interaction; AAS-driven HTN is a key indication where nebivolol becomes useful.
• Tadalafil / sildenafil: Mild additive BP drop (both vasodilate via NO); nebivolol's NO arm is theoretically additive with PDE5 inhibitor effect. Generally safe at standard doses; monitor BP first time combining.

Nebivolol's CYP profile

• Substrate: CYP2D6 (primary, dominant pathway), CYP2C19 (minor).
• Inhibitor: None clinically significant.
• Inducer: None.

Specific interactions worth flagging

• CYP2D6 strong inhibitors raise nebivolol exposure dramatically. Paroxetine, fluoxetine (Prozac), bupropion (Wellbutrin), quinidine, terbinafine (Lamisil), diphenhydramine (chronic high dose). Mechanism: convert EM phenotype effectively to PM. Practical effect: 2-5× higher AUC. If unavoidable, halve nebivolol dose. For this archetype: bupropion is on the conditional V5 list — if it ever enters daily use alongside nebivolol, dose-halve nebivolol.
• CYP2D6 weak inhibitors: sertraline, citalopram, escitalopram — modest exposure increase, usually clinically insignificant.
• NSAIDs can blunt antihypertensive effect (prostaglandin pathway); avoid chronic high-dose.
• Digoxin: additive bradycardia and AV-block risk; monitor HR and digoxin levels.
• Alcohol: additive vasodilation and BP drop. Not relevant for this archetype (zero alcohol).
• Cimetidine: mild CYP2D6 inhibition, modest exposure increase.

• CYP2D6 polymorphism — most clinically relevant variable for nebivolol of any beta-blocker.
  • Extensive metabolizers (~93% Caucasians): standard 5 mg starting dose.
  • Intermediate metabolizers: standard dose, monitor.
  • Poor metabolizers (~7% Caucasians): 8-fold higher exposure at standard dose. Start 2.5 mg/day, titrate cautiously, expect longer half-life (30-50 hr).
  • Ultrarapid metabolizers (~3-5%): lower exposure, may need higher doses or consider alternative (e.g., bisoprolol, less CYP2D6-dependent).
• Action item for users in this archetype: When 23andMe results land June 2026 and are run through Promethease/GeneSight, confirm CYP2D6 status. This applies to propranolol and nebivolol both; nebivolol is the more PK-sensitive of the two.
• β1 adrenergic receptor (ADRB1) Arg389Gly polymorphism. Arg389 carriers show better response to β1-selective blockers (including nebivolol). Modest clinical effect; mostly relevant in HF cohorts.
• β3 adrenergic receptor (ADRB3) Trp64Arg polymorphism. Theoretical relevance to the NO-mediated arm of nebivolol's mechanism; no clinical-grade dosing implications established.
• No HLA association for adverse reactions; standard surveillance applies.

Strategic note: Nebivolol requires an actual diagnosis (HTN, HF, or arrhythmia) to obtain via Rx — unlike propranolol which has a recognized off-label PRN indication for performance anxiety, nebivolol has no comparable off-label use. This means the user cannot pre-stockpile nebivolol the way he might propranolol. The relevant access path is: confirmed BP elevation → cardiology/PCP visit → standard prescription. This is documented as background; not currently actionable.

Baseline (before starting)

• Resting HR (Oura) — 14-day average baseline.
• Resting BP (cuff) — 3-reading average baseline; ideally a 7-day morning average.
• Max HR during conditioning workout — for athletic-impact context.
• Lipid panel — TC, LDL, HDL, TG, ApoB.
• Fasting glucose, HbA1c — beta-blocker class can drift insulin sensitivity; nebivolol is neutral but baseline matters.
• HRV overnight (Oura) — 14-day baseline.
• CYP2D6 phenotype — from 23andMe / Promethease (post-June 2026).
• Hepatic panel (ALT, AST) — confirm no hepatic impairment (contraindication).
• Erectile function self-report — IIEF-5 questionnaire baseline.
• Asthma history — confirm absence; high β1-selectivity is forgiving but not zero risk.
• ECG — PR interval, QTc, AV conduction; necessary baseline for chronic beta-blocker use.

During use (chronic)

• Resting HR weekly (Oura) — confirm steady-state effect.
• BP cuff readings 3×/week for first month; weekly thereafter.
• Subjective effect log: energy, exercise tolerance, sexual function, sleep, mood — any drift from baseline.
• Lipids and fasting glucose at 3-month and 6-month marks — confirm metabolic neutrality.
• Liver enzymes annually — given hepatic metabolism.
• Exercise tolerance: track training HR zones, perceived exertion, workout completion rate.